Hologic (NASDAQ:HOLX) Releases Q2 2025 Earnings Guidance

Hologic (NASDAQ:HOLX) updated its second quarter 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 1.000-1.030 for the period, compared to the consensus earnings per share estimate of 1.040. The company issued revenue guidance of $995.0 million-$1.0 billion, compared to the consensus revenue estimate of $1.0 billion. Hologic also updated its FY 2025 guidance to 4.250-4.350 EPS.

Analyst Ratings Changes

Several brokerages have commented on HOLX. Raymond James restated an “outperform” rating and issued a $90.00 target price (down previously from $95.00) on shares of Hologic in a research note on Thursday. JPMorgan Chase & Co. lifted their price target on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Morgan Stanley dropped their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. UBS Group boosted their price target on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, Stephens restated an “overweight” rating and issued a $84.00 price target on shares of Hologic in a research report on Thursday. Ten research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.77.

Hologic Stock Performance

Shares of HOLX traded down $0.60 during mid-day trading on Friday, hitting $64.86. 1,344,720 shares of the company’s stock were exchanged, compared to its average volume of 2,486,483. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $14.64 billion, a P/E ratio of 19.48, a P/E/G ratio of 2.35 and a beta of 0.98. Hologic has a fifty-two week low of $64.54 and a fifty-two week high of $84.67. The business’s 50 day moving average is $72.63 and its two-hundred day moving average is $77.86.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. On average, equities analysts expect that Hologic will post 4.28 earnings per share for the current year.

Insider Buying and Selling

In other news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.88% of the stock is owned by corporate insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.